Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps
Bluebird bio receives non-binding bid for up to $110.5 million
Bluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- Update